NCT06704204View on ClinicalTrials.gov

Long-acting Injectable Antiretroviral Treatment to Improve HIV Treatment Among Justice-involved Persons Being Released to the Community

Not yet recruitingOBSERVATIONAL
Enrollment

20

Participants

Timeline

Start Date

February 28, 2025

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2025

Conditions
HIV
Interventions
DRUG

The first FDA-approved LAI ART regimen includes an integrase inhibitor, cabotegravir (CAB), and a non-nucleoside reverse transcriptase inhibitor, rilpivirine (RPV) combined 4 wks

To date, there have been no studies looking at the use of LAI ART among justice involved PWH, yet a significant opportunity exists to improve HIV treatment outcomes in this high risk population.30

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

The Miriam Hospital

OTHER

NCT06704204 - Long-acting Injectable Antiretroviral Treatment to Improve HIV Treatment Among Justice-involved Persons Being Released to the Community | Biotech Hunter | Biotech Hunter